Anticancer therapy at end-of-life: A retrospective cohort study
Open Access
- 8 May 2024
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 63, 313-321
Abstract
Background: A significant proportion of patients with incurable cancer receive systemic anticancer therapy (SACT) within their last 30 days of life (DOL). The treatment has questionable benefit, nevertheless is considered a quality indicator of end-of-life (EOL) care. This retrospective cohort study aims to investigate the rates and potential predictors of SACT and factors associated with SACT within the last 30 DOL. The study also evaluates the scope of Eastern Cooperative Oncology Group (ECOG) performance status and the modified Glasgow prognostic score (mGPS) as decision-making tools for oncologists. Patients and Material: This review of medical records included 383 patients with non-curable cancer who died between July 2018 and December 2019. Descriptive statistics with Chi-squared tests and regression analysis were used to identify factors associated with SACT within the last 30 DOL. Results: Fifty-seven (15%) patients received SACT within the last 30 DOL. SACT within 30 last DOL was associated with shorter time from diagnosis until death (median 234 days vs. 482, p = 0.008) and ECOG score < 3 30 days prior to death (p = 0.001). Patients receiving SACT during the last 30 DOL were more likely to be hospitalised and die in hospital. ECOG and mGPS score were stated at start last line of treatment only in 139 (51%) and 135 (49%) respectively. Interpretation: Those with short time since diagnosis tended to receive SACT more frequently the last 30 DOL. The use of mGPS as a decision-making tool is modest, and there is lack in documentation of performance status.Keywords
This publication has 42 references indexed in Scilit:
- Systemic Anticancer Therapy at the End of Life—Changes in Usage Pattern in the Immunotherapy EraJAMA Oncology, 2022
- Care of the adult cancer patient at the end of life: ESMO Clinical Practice GuidelinesESMO Open, 2021
- Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitorsCancer, 2019
- Course of Quality of Life After Radiation Therapy for Painful Bone Metastases: A Detailed Analysis From the Dutch Bone Metastasis StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2016
- Chemotherapy Use, Performance Status, and Quality of Life at the End of LifeJAMA Oncology, 2015
- The Accuracy of Physicians' Clinical Predictions of Survival in Patients With Advanced CancerJournal of Pain and Symptom Management, 2015
- Mortality within 30days following systemic anti-cancer therapy, a review of all cases over a 4year period in a tertiary cancer centreEuropean Journal of Cancer, 2015
- A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancerTumor Biology, 2014
- The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancerCancer Treatment Reviews, 2013
- Update on the Systematic Review of Palliative Radiotherapy Trials for Bone MetastasesClinical Oncology, 2012